Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

By H. Grier, M. Krailo, N. Tarbell, M. Link, C. Fryer, D. Pritchard, M. Gebhardt, P. Dickman, E. Perlman, P. Meyers and 5 more. New England Journal of Medicine, 2003

1,231 citations recorded by the source corpus.

Subfields: Genetics, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/388631137a36abe4ba9cf2811dab19493322af31

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

N. Gaspar
D. Hawkins
A. Bleyer
Malcolm A. Smith
U. Dirksen
R. Womer
I. Lewis
R. Barr

Citations in the corpus

The distinctive biology of cancer in adolescents and young adults (2008, background): “On the other hand, in a larger randomized trial of 518 patients with Ewing sarcoma, conducted by the Children's Oncology Group (COG), older patients were again noted to have a worse outcom”
Outcomes for children and adolescents with cancer: challenges for the twenty-first century. (2010, background): “The improved outcome noted in the early 1990s and thereafter may reflect benefits of ifosfamide and etoposide, which in a randomized study improved outcome in patients with localized Ewing sarcoma family of tumors.(32) For both osteosarcoma and Ewing sarcoma, patients presenting with metastatic dise”
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. (2012, background): “The North American intergroup Ewing sarcoma study INT-0091 demonstrated that a regimen of alternating vincristine-doxorubicin-cyclophosphamide (VDC) and ifosfamide-etoposide (IE) was superior to VDC, with approximately 70% of patients with localized tumors apparently cured.(5) In the absence of new ”
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. (2015, methodology): “The randomized INT-0091 trial demonstrated the benefit of adding the IE combination to vincristine, doxorubicin, and cyclophosphamide (VDC) in localized ES, but there was no benefit observed in patients with metastatic disease.(3) Other investigations that replaced cyclophosphamide with ifosfamide i”